| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Department of Respiratory Medicine, University of Maastricht, Maastricht, Netherlands (AMWJS, RB, and EFW) and the Asthma Centre Hornerheide, Horn, Netherlands (CAW)
2 Reprints not available. Address correspondence to AMWJ Schols, Department of Respiratory Medicine, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands. E-mail: a.schols{at}pul.unimaas.nl.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: To compare the contributions of low fat-free mass and low fat mass to mortality, we assessed the association between body composition and mortality in COPD.
Design: We studied 412 patients with moderate-to-severe COPD [Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) stages II–IV, forced expiratory volume in 1 s of 36 ± 14% of predicted (range: 19–70%). Body composition was assessed by using single-frequency bioelectrical impedance. Body mass index, fat-free mass index, fat mass index, and skeletal muscle index were calculated and related to recently developed reference values. COPD patients were stratified into defined categories of tissue-depletion pattern. Overall mortality was assessed at the end of follow-up.
Results: Semistarvation and muscle atrophy were equally distributed among disease stages, but the highest prevalence of cachexia was seen in GOLD stage IV. Forty-six percent of the patients (n = 189) died during a maximum follow-up of 5 y. Cox regression models, with and without adjustment for disease severity, showed that fat-free mass index (relative risk: 0.90; 95% CI: 0.84, 0.96; P = 0.003) was an independent predictor of survival, but fat mass index was not. Kaplan-Meier and Cox regression plots for cachexia and muscle atrophy did not differ significantly.
Conclusions: Fat-free mass is an independent predictor of mortality irrespective of fat mass. This study supports the inclusion of body-composition assessment as a systemic marker of disease severity in COPD staging.
Key Words: Mortality • chronic obstructive pulmonary disease • COPD • body composition • muscle mass • lung function
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Lung function
Lung function testing included spirometry and resting arterial blood gases. Forced expiratory volume in 1 s (FEV1) and inspiratory vital capacity (IVC) were measured with a wet spirometer by using the highest value of 
3 acceptable spirometric maneuvers. Prebronchodilation and postbronchodilation FEV1 and IVC were expressed as a percentage of the reference values (14). Arterial blood gases were drawn by puncture of the at-rest brachial artery while the subjects breathed room air. Arterial oxygen tension (PaO2) and arterial carbon dioxide tension (PaCO2) were analyzed with the use of a blood gas analyzer (ABL 330; Radiometer, Copenhagen, Denmark).
Body composition
Body height was measured to the nearest 0.5 cm while the subjects were barefoot and standing (WM 715; Lameris, Breukelen, Netherlands). Body weight was measured on a calibrated beam scale (model 708; Seca, Hamburg, Germany). Body composition was assessed by using single-frequency BIA (50 Hz; Xitron Technologies, San Diego, CA). All measurements were performed by the same trained dietitian at a standardized time after breakfast. FFM was calculated by using disease-specific equations (13). FM was calculated as total body weight minus FFM. A prerequisite of the use of BIA is that the equations used to transform the measured resistance into FFM or total body water are adapted to the individuals measured and have been tested for validity in the populations for which they are intended. In these conditions, BIA measurements are accurate and comparable to other techniques used to assess body composition. BIA has been extensively validated and evaluated in patients with COPD. The equations used were validated against deuterium dilution as the reference method, whereas other studies showed good association with dual-exposure X-ray absorptiometry (15, 16). The skeletal muscle index (SMI) was determined according to the equations used by Janssen et al (12).
Follow-up
Mortality was assessed on 31 January 1993. Patients were followed for 2–5 y or until death, whichever came first. Mortality was assessed as overall mortality due to all causes.
Statistical analysis
BMI, FFM index (FFMI), and FM index (FMI) were calculated by dividing body weight (in kg), FFM, and FM, respectively, by height (in m) squared to adjust for body surface area. Patients were stratified by body composition into 4 categories, as follows. Patients in category 1 (cachexia) had BMI <21 and FFMI <16 (men) or <15 (women); patients in category 2 (semistarvation) had BMI <21 and FFMI 16 (men) or 15 (women); patients in category 3 (muscle atrophy) had BMI 21 and FFMI <16 (men) or <15 (women); and patients in category 4 (no impairment) had BMI 21 and FFMI 16 (men) or 15 (women).
The cutoff for FFMI is based on the linear association between FFM and body weight in normal-weight to underweight COPD patients as described by Baarends et al (8). In earlier publications, our group showed that these cutoffs are discriminative for exercise capacity (7) and health status (17). FFMI and FMI were compared with the sex-specific percentiles reported by Schutz et al (18). As an additional characterization, the SMI was measured, as proposed by Janssen et al, for a comparison of the total study population as well as the subgroups with results from the third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 (19). The percentage of patients theoretically at risk for physical disability was assessed by using the cutoffs for physical disability risk set by Janssen et al. Subjects from NHANES III were classified as physically disabled (ie, having difficulty performing activities of daily living) if they answered "yes" to either or both of the following questions: 1) "Because of any impairment or health problem, do you need the help of other persons with personal care needs, such as eating, bathing, dressing, or getting around at home?" and 2) "Because of any impairment or health problem, do you need the help of other persons in handling routine needs, such as everyday household chores, doing necessary business, shopping, or getting around for other purposes?"
In the study by Janssen et al (19), the cutoffs for severe physical disability risk were set at SMI 
5.75 (women) or 8.50 (men), and those for moderate physical disability risk were set at SMI 6.75 and >5.75 (women) or 10.75 and >8.50 (men).
Results are presented as mean (±SD) for all variables that were normally distributed. Univariate analysis was performed by using the Kaplan-Meier method. A log-rank chi-square test for comparing survival between groups was used to analyze the association between depletion pattern and survival. The Cox proportional hazards model was used to quantify the relation between mortality and body composition (ie, FFMI and FMI), age, sex (0 = women, 1 = men), disease severity [PaO2, PaCO2, and FEV1 (% of predicted) as continuous variables], and GOLD classification (as a categorized variable). Lung function criteria that defined the GOLD stages were normal lung function, GOLD 0 (at risk); the ratio of FEV1 to IVC <70% and FEV1 80%, GOLD I (mild); FEV1:IVC <70% and FEV1 <80% and 50%, GOLD II (moderate); FEV1:IVC <70% and FEV1 <50% and 30%, GOLD III (severe); and FEV1:IVC <70% and FEV1<30% or FEV1 <50% and PaO2 <8.0 kPa, GOLD IV (very severe).
The relative risk (RR) corresponding to a risk factor in this model is the exponential of the regression coefficient. The differences in distribution of body composition categories in GOLD stages II–IV were tested by using the chi-square test.
We performed all analyses with and without inclusion of the variable smoking (0 = no smoking or former smoking, 1 = current smoking). However, the cumulative pack-year exposure was high in all patients, and status as a former smoker was not objectively verified (eg, by cotinine measurements in saliva). Therefore, smoking was not associated with mortality in these subjects, and we decided to report only the results without this variable in the model.
A two-sided value of P < 0.05 was considered significant. Baseline comparisons between groups stratified by disease severity or body composition were performed by using an unpaired Student’s t test with Bonferroni correction for multiple comparisons. Data were analyzed by using SPSS for WINDOWS statistical software (version 11.0; SPSS Inc, Chicago, IL).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The mean age of the study group was 64 ± 9 y, 77% were male, and mean FEV1 was 36 ± 14% of predicted (range: 19–70%). Because there was a significant difference between men and women in BMI, FFMI, and FMI (all: P < 0.05), we stratified mean values for FFMI, FMI, and SMI of the 4 body-composition categories by sex in Table 2 and related them separately to the sex-specific reference values reported by Schutz et al (18) and Janssen et al (19). The proportions of men to women did not differ significantly between the 4 body-composition categories. In categories 1 and 3, mean FFMI was below the 10th or even the 5th percentile in both male and female patients. Mean FFMI in categories 2 and 4 was within median range (<50th percentile) except for male patients in category 2, whose values were below the 10th percentile. FMI did not differ significantly between categories 1 and 2 or between categories 3 and 4 in either men or women. Although female patients with a low BMI had an FMI below the 10th percentile, male patients had an FMI within the median range. This indicates a sex-specific shift in body composition. When we applied the criteria for SMI and related physical disability that Janssen et al (19) used, a high proportion of the total patient population was characterized as being at moderate (51%) or high (31%) risk. In line with that study, male patients in the current study were at higher risk of physical disability than were female patients. On univariate Cox regression analysis, however, the association between SMI and survival in the current study did not differ significantly between the men (RR: 0.75; 95% CI: 0.65, 0.86) and the women (RR: 0.75; 95% CI: 0.51, 0.99). Furthermore, classification of the patients in the 4 categories clearly showed that, independent of sex, significantly (P < 0.001) more patients were at moderate to high risk of disability in the cachexia and muscle atrophy categories (ie, 1 and 3) than in semistarvation and no-impairment categories (ie, 2 and 4) (Table 2).
|
|
, body-composition categories are linked to GOLD stage of disease severity. Most of the patients had advanced COPD (GOLD II, n = 71; GOLD III, n = 134; and GOLD IV, n = 207). Cachexia was significantly (P = 0.001) more prevalent in GOLD stage IV than in GOLD stages II and III.
|
). In addition, Cox stepwise regression analysis showed that FFMI was selected when BMI was no longer significant (data not shown) when entered as either an absolute value or as dichotomized BMI (< or 21); this indicates that FFMI is a stronger predictor for mortality than is BMI. After multivariate analysis, adjusted only for age (P = 0.001) and sex (NS) (model 1) or also adjusted for FEV1 [either in vol/s (data not shown) or as a percentage of predicted (P = 0.037)], IVC (NS), and resting arterial blood gases (NS) (model 2), FFMI was an independent predictor of mortality (P = 0.001 and 0.003 for model 1 and model 2, respectively), but FMI was not (Table 3). Although only a few patients were in the semistarvation category, the Kaplan-Meier plots for all the body-composition categories are shown in Figure 2. Survival was significantly (P < 0.001) less in patients with cachexia (median: 26 mo; 95% CI: 21, 31 mo) and muscle atrophy (median: 24 mo; 95% CI: 15, 33 mo) than in patients with semistarvation (median 36 mo; 95% CI: 28, 44 mo) or patients with no impairment (median: 47 mo; 95% CI: 37, 57 mo). The survival plot for the semistarvation category did not differ significantly from that of the no-impairment category during the first 3 y (Figure 2). In the last 2 y of the study, the survival curve of the semistarvation category diverged from that of the no-impairment category to resemble the survival curves of the cachexia and muscle atrophy categories.
|
|
. The RRs (95% CIs) of patients in the 3 tissue-depletion categories compared with those of patients in the no-impairment category were 1.91 (1.37, 2.67; P = 0.006), 1.23 (1.68, 2.24; NS), 1.96 (1.21, 3.17; P < 0.001) for categories 1 (cachexia), 2 (semistarvation), and 3 (muscle atrophy), respectively. Therefore, patients in both categories with low FFMI have a greater mortality risk than do patients with no impairment, and, thus, low BMI does not increase mortality risk beyond the increase due to low FFMI.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The findings of this study differ from those of population studies showing that an abundance of FM is particularly associated with increased cardiovascular disease–related mortality risk in overweight to obese subjects (reviewed in 21). The current study indicates that, in COPD patients, the association between FFMI and survival is independent of the amount of FM and that FFMI provides information to assist prognosis beyond that provided by BMI. Strikingly similar physical disability and mortality risks were seen in the cachexia and muscle atrophy categories, which indicated that a critical loss of muscle mass, not reflected in BMI, may be responsible for physical disability and greater mortality risk. In previous studies, we also showed significant differences in functional impairment such as exercise capacity measured by a 12-min walking test (7) or incremental cycle ergometry between patients in the cachexia and muscle atrophy categories relative to those in the semistarvation and no-impairment categories. Remarkably, the survival plot of the semistarvation category did not differ significantly from that of the no-impairment category during the first 3 y, whereas, thereafter, mortality was clearly higher in the semistarvation category. One could speculate that these patients initially have less mortality risk because of (relative) preservation of FFM but that, in due course, they are at greater risk of a critical loss of FFM. This hypothesis, however, should be confirmed in a longitudinal study using repeated measurements of body composition. The current study also showed remarkable sex-specific differences in body composition and disability risk from the reference values, and those differences warrant further investigation. As compared with the data of Schutz et al (18), the shift in body composition toward less FFM and more FM was more striking in men than in women. One could argue that the male patients in the semistarvation category were not truly starving according to the external standards of Schutz et al (18). However, those patients clearly had lower FM than did patients in categories 3 and 4. Furthermore, in both the men and the women, comparison with the reference values of Janssen et al (19) showed that physical disability risk was clearly lower in categories 3 and 4, which confirmed previous studies relating those tissue-depletion categories to objective measures of skeletal function and exercise capacity (6-8). As was also indicated by Janssen et al (19), the SMI cutoffs were a significantly stronger predictor of physical disability in men than in women. This observation could indicate that SMI cutoffs should be adjusted. However, it might also be possible that the association between FFMI and physical disability risk, as judged by a questionnaire, really differs between males and females. This could reflect a different relation of body composition and functional capacity between males and females. It could also reflect a different coping strategy between males and females toward the functional limitations consequent to their chronic disease.
The relative preservation of FM in COPD patients could result from inactivity as a consequence of the progressive disability due to the disease. It could also be a consequence of biological factors such as a derangement in (fat) oxidative metabolism, as indicated by impaired ß-adrenoceptor–mediated lipolysis, which reduced fat mobilization (22). That, in turn, could lead to an increase in glucose turnover and protein utilization, as was reflected in an increased whole-body protein turnover (23). The abovementioned shift in body composition could therefore be an indication of either accelerated sarcopenia or an early phase of cachexia. Because cachexia was seen mostly in GOLD IV COPD patients (characterized not only by severe airflow obstruction but also by PaO2 <8.0 kPa), the loss of FM as well as of FFM might be related to specific effects of hypoxia on energy balance.
FFMI was associated with mortality with and without adjustment for static lung volumes and resting arterial blood gases. These markers are traditionally used to define disease severity and are included in the recent GOLD stages, but that does not exclude the possibility that other lung function markers might affect FFMI or the relation between FFMI and mortality. In particular, adjustment for the degree of emphysema would have been interesting, because previous studies showed that FFMI correlated with the diffusing capacity for carbon monoxide as a hallmark of emphysema (6). Furthermore, weight loss and low FFMI were significantly more common in patients with emphysema, as assessed by high-resolution computed tomography scanning, than in patients with chronic bronchitis (24). The process of emphysema might induce weight loss or loss of FFM, but weight loss or loss of FFM also may induce emphysema. Post-mortem studies of persons who died in the Warsaw Ghetto during World War II suggested that death due to starvation was associated with pulmonary emphysema (25). In line with this observation but using advanced techniques to assess emphysema, an elegant study recently showed the presence of emphysema-like changes in the lungs of chronically malnourished anorexia nervosa patients (5).
On the basis of numerous reports showing an association between BMI and mortality risk in COPD, Celli at al (26) recently proposed that clinical staging for COPD should be based not only on spirometry and resting arterial blood gases, eg, the recent GOLD criteria, but also on BMI, exercise capacity, and dyspnea score. The results of the current study indicate that FFMI could be an even better independent predictor of systemic disease severity than is BMI.
The current study was limited by a skewed distribution of the study population toward more males and the more severe GOLD stages III and IV. In addition, categories 2 and 3 (semistarvation and muscle atrophy) were relatively small. Longitudinal studies with repeated assessments of body composition are needed to increase our knowledge of the sequence of body-composition changes so that we can better target therapeutic interventions. In advanced stages of disease, low FFM has already been clearly identified as a primary determinant of perceived disability, handicap, and health care costs, and it is therefore currently considered an important target for therapy (7, 17, 19, 27). Several studies specifically aimed therapeutic interventions at the accretion of muscle mass in patients with advanced COPD to improve functional capacity (28-33). The current study indicates that therapeutic strategies should depend not on BMI but on body composition. Although the studies by our group (28, 29, 31, 34) indicated that current therapeutic modalities can increase FFM, the extent to which improvement in FFM per se is reflected in other relevant outcome measures, including mortality, and the minimal clinically effective increase in FFM remain to be investigated.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  M.-A. Caron, R. Debigare, P. N. R. Dekhuijzen, and F. Maltais Comparative assessment of the quadriceps and the diaphragm in patients with COPD J Appl Physiol, September 1, 2009; 107(3): 952 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Graat-Verboom, E. F. M. Wouters, F. W. J. M. Smeenk, B. E. E. M. van den Borne, R. Lunde, and M. A. Spruit Current status of research on osteoporosis in COPD: a systematic review Eur. Respir. J., July 1, 2009; 34(1): 209 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. W. J. Schols Nutritional rehabilitation: from pulmonary cachexia to sarcoPD Eur. Respir. J., May 1, 2009; 33(5): 949 - 950. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bolton, M. Stone, P. Edwards, J. Duckers, W. Evans, and D. Shale Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease Chronic Respiratory Disease, May 1, 2009; 6(2): 81 - 87. [Abstract] [PDF]
|
|
|
|
 |
|
 E Barreiro, R Rabinovich, J Marin-Corral, J A Barbera, J Gea, and J Roca Chronic endurance exercise induces quadriceps nitrosative stress in patients with severe COPD Thorax, January 1, 2009; 64(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. E. Franssen, H. P. Sauerwein, E. P. A. Rutten, E. F. M. Wouters, and A. M. W. J. Schols Whole-body resting and exercise-induced lipolysis in sarcopaenic patients with COPD Eur. Respir. J., December 1, 2008; 32(6): 1466 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F M E Franssen, D E O'Donnell, G H Goossens, E E Blaak, and A M W J Schols Obesity and the lung: 5 {middle dot} Obesity and COPD Thorax, December 1, 2008; 63(12): 1110 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sauvaget, K. Ramadas, G. Thomas, J. Vinoda, S. Thara, and R. Sankaranarayanan Body mass index, weight change and mortality risk in a prospective study in India Int. J. Epidemiol., October 1, 2008; 37(5): 990 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. King, F. Cordova, and S. M. Scharf Nutritional Aspects of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 519 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Wagner Possible mechanisms underlying the development of cachexia in COPD Eur. Respir. J., March 1, 2008; 31(3): 492 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Poulain, M. Doucet, V. Drapeau, G. Fournier, A. Tremblay, P. Poirier, and F. Maltais Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease Chronic Respiratory Disease, February 1, 2008; 5(1): 35 - 41. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. J. van der Velden, A. M. W. J. Schols, J. Willems, M. C. J. M. Kelders, and R. C. J. Langen Glycogen Synthase Kinase 3 Suppresses Myogenic Differentiation through Negative Regulation of NFATc3 J. Biol. Chem., January 4, 2008; 283(1): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Haranath, B. S. Park, M. Osborne, S. Budweiser, and R. A. Jorres Body Mass Index in COPD Mortality: Is It All in the Water? Chest, January 1, 2008; 133(1): 318 - 319. [Full Text] [PDF]
|
|
|
|
|
|
H. R Gosker, M. P Zeegers, E. F M Wouters, and A. M W J Schols Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis Thorax, November 1, 2007; 62(11): 944 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Agusti Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should) Proceedings of the ATS, October 1, 2007; 4(7): 522 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Varraso, T. T Fung, R G. Barr, F. B Hu, W. Willett, and C. A Camargo Jr Prospective study of dietary patterns and chronic obstructive pulmonary disease among US women Am. J. Clinical Nutrition, August 1, 2007; 86(2): 488 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Doucet, A. P. Russell, B. Leger, R. Debigare, D. R. Joanisse, M.-A. Caron, P. LeBlanc, and F. Maltais Muscle Atrophy and Hypertrophy Signaling in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 261 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ischaki, G. Papatheodorou, E. Gaki, I. Papa, N. Koulouris, and S. Loukides Body Mass and Fat-Free Mass Indices in COPD: Relation With Variables Expressing Disease Severity Chest, July 1, 2007; 132(1): 164 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. van den Bemt, T. Schermer, and C. van Weel Rational monitoring of COPD: where do current clinical guidelines stand? Eur. Respir. J., June 1, 2007; 29(6): 1078 - 1081. [Full Text] [PDF]
|
|
|
|
|
|
E. F. M. Wouters Decision Making in Chronic Hypercapnic Respiratory Failure: A Real Challenge! Chest, June 1, 2007; 131(6): 1622 - 1624. [Full Text] [PDF]
|
|
|
|
|
|
S. Budweiser, R. A. Jorres, T. Riedl, F. Heinemann, A. P. Hitzl, W. Windisch, and M. Pfeifer Predictors of Survival in COPD Patients With Chronic Hypercapnic Respiratory Failure Receiving Noninvasive Home Ventilation Chest, June 1, 2007; 131(6): 1650 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C Steiner Sarcopaenia in chronic obstructive pulmonary disease Thorax, February 1, 2007; 62(2): 101 - 103. [Full Text] [PDF]
|
|
|
|
|
|
C. E Bolton, R. Broekhuizen, A. A Ionescu, L. S Nixon, E. F M Wouters, D. J Shale, and A. M W J Schols Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD Thorax, February 1, 2007; 62(2): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B Swallow, D. Reyes, N. S Hopkinson, W. D-C Man, R. Porcher, E. J Cetti, A. J Moore, J. Moxham, and M. I Polkey Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease Thorax, February 1, 2007; 62(2): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Schooling, T. H. Lam, Z. B. Li, S. Y. Ho, W. M. Chan, K. S. Ho, M. K. Tham, B. J. Cowling, and G. M. Leung Obesity, physical activity, and mortality in a prospective chinese elderly cohort. Arch Intern Med, July 24, 2006; 166(14): 1498 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Poulain, M. Doucet, G. C. Major, V. Drapeau, F. Series, L.-P. Boulet, A. Tremblay, and F. Maltais The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. Can. Med. Assoc. J., April 25, 2006; 174(9): 1293 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marti, X. Munoz, J. Rios, F. Morell, and J. Ferrer Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur. Respir. J., April 1, 2006; 27(4): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Rutten, F. M. Franssen, M. P. Engelen, E. F. Wouters, N. E. Deutz, and A. M. Schols Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 829 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S Hopkinson, K. I Eleftheriou, J. Payne, A. H Nickol, E. Hawe, J. Moxham, H. Montgomery, and M. I Polkey +9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 912 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. M. Wouters Muscle Wasting in Chronic Obstructive Pulmonary Disease: To Bother and to Measure! Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
D D Sin and S F P Man Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link? Thorax, January 1, 2006; 61(1): 1 - 3. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
); muscle atrophy (n = 40; 
); semistarvation (n = 23; 
). Cachexia was significantly (P = 0.001) more prevalent in GOLD stage IV (n = 207) than in GOLD stage II (n = 71) or III (n = 134).
